SBIO ALPS Medical Breakthroughs ETF
Kuotasi per Aug 27, 2026 19:37 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Penutupan Sebelumnya | 69.66 | Rentang Harian | 69.00 – 69.89 |
| Kisaran 52 Minggu | 34.66 – 70.85 | Volume | 22.44K |
| Volume Rata-Rata | 39.97K | AUM | $242.4M (Aug 27, 2026) |
| Expense Ratio | 0.50% | Yield (TTM) | — |
| NAV | 70.27 | Premium/Diskon | -0.78% indikatif |
| Inception | Dec 30, 2014 | Kepemilikan | 103 |
| Penerbit | ALPS Funds | Bursa | AMEX |
| Kategori | Biotech | Indeks yang Dilacak | Tidak tercantum dalam data sumber |
| CUSIP | 00162Q593 | ISIN | US00162Q5936 |
| Manajemen | Pasif / mengikuti indeks (sesuai deskripsi penerbit) | ||
Tentang ETF ini
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Deskripsi dari penyedia data dana · profil per Aug 27, 2026.
Grafik Harga
Harga penutupan harian (imbal hasil harga, bukan imbal hasil total). Garis perbandingan dinormalisasi ke perubahan persentase dari awal rentang waktu. Sumber: Financial Modeling Prep.
Kinerja
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Return harga | +8.03% | +29.43% | +33.37% | +36.00% | +99.14% | +33.15% | +8.36% | +11.07% | +9.25% |
| Total return | +8.03% | +29.43% | +33.37% | +36.00% | +99.14% | +34.82% | +9.16% | +12.00% | +10.03% |
* Disetahunkan. Total imbal hasil menggunakan seri harga yang disesuaikan dengan dividen (distribusi diinvestasikan kembali); imbal hasil harga menggunakan harga penutupan tanpa penyesuaian. Kinerja hingga Aug 26, 2026. Kinerja masa lalu tidak menjamin hasil di masa depan.
Biaya
| Expense ratio bersih | 0.50% | Biaya tahunan untuk investasi $10.000 | $50.00 |
Hanya kalkulasi ilustrasi: expense ratio × $10.000. Tidak termasuk biaya perdagangan, selisih bid/ask, pajak, dan perubahan nilai investasi. Detail expense ratio bruto vs. neto dan setiap pengabaian biaya tersedia dalam prospektus.
Kepemilikan
Kepemilikan per Aug 22, 2026 — tanggal pelaporan portofolio dari penyedia data; kepemilikan bukan posisi langsung. 107 baris dalam basis data.
| # | Kepemilikan | Ticker | Bobot | Saham | Nilai Pasar |
|---|---|---|---|---|---|
| 1 | Crinetics Pharmaceuticals Inc. | CRNX | 4.43% | 123.57K | $10.5M |
| 2 | Apogee Therapeutics Inc. | APGE | 4.14% | 72.59K | $9.8M |
| 3 | CG oncology Inc. | CGON | 3.49% | 103.46K | $8.3M |
| 4 | Oruka Therapeutics Inc. | ORKA | 3.23% | 70.63K | $7.6M |
| 5 | Travere Therapeutics Inc. | TVTX | 3.03% | 109.01K | $7.2M |
| 6 | Dianthus Therapeutics Inc. | DNTH | 3.01% | 64.07K | $7.1M |
| 7 | Xenon Pharmaceuticals Inc. | XENE | 2.91% | 113.24K | $6.9M |
| 8 | ACADIA Pharmaceuticals Inc. | ACAD | 2.50% | 200.65K | $5.9M |
| 9 | Definium Therapeutics Inc. | DFTX | 2.43% | 127.93K | $5.7M |
| 10 | Edgewise Therapeutics Inc. | EWTX | 2.36% | 126.30K | $5.6M |
| 11 | Dyne Therapeutics Inc. | DYN | 2.14% | 193.98K | $5.1M |
| 12 | Amylyx Pharmaceuticals Inc. | AMLX | 2.14% | 130.53K | $5.0M |
| 13 | VeraDermics Inc. | MANE | 2.13% | 48.91K | $5.0M |
| 14 | Relay Therapeutics Inc. | RLAY | 2.10% | 255.24K | $5.0M |
| 15 | Denali Therapeutics Inc. | DNLI | 1.96% | 186.20K | $4.6M |
| 16 | Structure Therapeutics Inc. | GPCR | 1.73% | 83.40K | $4.1M |
| 17 | Ideaya Biosciences Inc. | IDYA | 1.73% | 103.06K | $4.1M |
| 18 | Newamsterdam Pharma Co. NV | NAMS | 1.62% | 137.16K | $3.8M |
| 19 | Immunome Inc. | IMNM | 1.60% | 132.87K | $3.8M |
| 20 | Celldex Therapeutics Inc. | CLDX | 1.57% | 91.93K | $3.7M |
| 21 | MBX Biosciences Inc. | MBX | 1.56% | 55.75K | $3.7M |
| 22 | Tarsus Pharmaceuticals Inc. | TARS | 1.55% | 50.36K | $3.7M |
| 23 | Disc Medicine Inc. | IRON | 1.51% | 44.78K | $3.6M |
| 24 | SELLAS Life Sciences Group Inc. | SLS | 1.43% | 218.37K | $3.4M |
| 25 | Zai Lab Ltd. | ZLAB | 1.41% | 127.72K | $3.3M |
| 26 | Viridian Therapeutics Inc. | VRDN | 1.33% | 129.54K | $3.1M |
| 27 | Nektar Therapeutics | NKTR | 1.24% | 39.68K | $2.9M |
| 28 | BioCryst Pharmaceuticals Inc. | BCRX | 1.21% | 298.31K | $2.8M |
| 29 | Nuvation Bio Inc. | NUVB | 1.20% | 408.64K | $2.8M |
| 30 | Vera Therapeutics Inc. | VERA | 1.15% | 84.24K | $2.7M |
| 31 | Rapport Therapeutics Inc. | RAPP | 1.14% | 56.02K | $2.7M |
| 32 | Mineralys Therapeutics Inc. | MLYS | 1.12% | 103.32K | $2.7M |
| 33 | Kailera Therapeutics Inc. | KLRA | 1.10% | 152.08K | $2.6M |
| 34 | Vericel Corp. | VCEL | 1.08% | 59.83K | $2.6M |
| 35 | Generate Biomedicines Inc. | GENB | 1.02% | 150.26K | $2.4M |
| 36 | Xencor Inc. | XNCR | 1.02% | 86.71K | $2.4M |
| 37 | Zenas Biopharma Inc. | ZBIO | 1.01% | 73.95K | $2.4M |
| 38 | Palvella Therapeutics Inc. | PVLA | 1.00% | 16.69K | $2.4M |
| 39 | Stoke Therapeutics Inc. | STOK | 1.00% | 73.14K | $2.4M |
| 40 | Sarepta Therapeutics Inc. | SRPT | 0.98% | 123.72K | $2.3M |
| 41 | Agios Pharmaceuticals Inc. | AGIO | 0.98% | 69.73K | $2.3M |
| 42 | Immunocore Holdings PLC | IMCR | 0.93% | 59.69K | $2.2M |
| 43 | Lakefront Biotherapeutics NV | LKFT | 0.93% | 76.12K | $2.2M |
| 44 | Compass Pathways PLC | CMPS | 0.89% | 158.42K | $2.1M |
| 45 | Taysha Gene Therapies Inc. | TSHA | 0.87% | 337.29K | $2.1M |
| 46 | Maze Therapeutics Inc. | MAZE | 0.81% | 64.98K | $1.9M |
| 47 | Bicara Therapeutics Inc. | BCAX | 0.78% | 76.87K | $1.8M |
| 48 | Tyra Biosciences Inc. | TYRA | 0.77% | 69.83K | $1.8M |
| 49 | LB Pharmaceuticals Inc. | LBRX | 0.68% | 33.77K | $1.6M |
| 50 | ArriVent Biopharma Inc. | AVBP | 0.67% | 54.66K | $1.6M |
| 51 | MeiraGTx Holdings PLC | MGTX | 0.66% | 108.25K | $1.6M |
| 52 | Seaport Therapeutics Inc. | SPTX | 0.65% | 63.03K | $1.5M |
| 53 | MannKind Corp. | MNKD | 0.64% | 362.62K | $1.5M |
| 54 | Vor BioPharma Inc. | VOR | 0.62% | 63.21K | $1.5M |
| 55 | Corvus Pharmaceuticals Inc. | CRVS | 0.61% | 99.02K | $1.4M |
| 56 | Alto Neuroscience Inc. | ANRO | 0.60% | 41.32K | $1.4M |
| 57 | Immatics NV | IMTX | 0.59% | 157.41K | $1.4M |
| 58 | Kura Oncology Inc. | KURA | 0.53% | 104.53K | $1.2M |
| 59 | Wave Life Sciences Inc. | WVE | 0.50% | 225.07K | $1.2M |
| 60 | Climb Bio Inc. | CLYM | 0.49% | 67.43K | $1.2M |
| 61 | Geron Corp. | GERN | 0.49% | 755.45K | $1.1M |
| 62 | Candel Therapeutics Inc. | CADL | 0.48% | 86.28K | $1.1M |
| 63 | Design Therapeutics Inc. | DSGN | 0.47% | 73.56K | $1.1M |
| 64 | Olema Pharmaceuticals Inc. | OLMA | 0.47% | 102.86K | $1.1M |
| 65 | Solid Biosciences Inc. | SLDB | 0.46% | 115.93K | $1.1M |
| 66 | Aclaris Therapeutics Inc. | ACRS | 0.45% | 164.47K | $1.1M |
| 67 | Theravance Biopharma Inc. | TBPH | 0.44% | 60.71K | $1.0M |
| 68 | SpyGlass Pharma Inc. | SGP | 0.42% | 37.87K | $1.0M |
| 69 | Rigel Pharmaceuticals Inc. | RIGL | 0.42% | 21.77K | $999.2K |
| 70 | 4D Molecular Therapeutics Inc. | FDMT | 0.41% | 61.57K | $974.6K |
| 71 | Oculis Holding AG | OCS | 0.37% | 67.32K | $880.9K |
| 72 | Allogene Therapeutics Inc. | ALLO | 0.36% | 406.46K | $849.5K |
| 73 | Tectonic Therapeutic Inc. | TECX | 0.35% | 22.23K | $836.3K |
| 74 | AgomAb Therapeutics NV | AGMB | 0.33% | 58.00K | $768.5K |
| 75 | Eikon Therapeutics Inc. | EIKN | 0.31% | 63.76K | $726.2K |
| 76 | Neurogene Inc. | NGNE | 0.30% | 18.61K | $718.7K |
| 77 | Altimmune Inc. | ALT | 0.30% | 229.02K | $712.2K |
| 78 | Delcath Systems Inc. | DCTH | 0.29% | 40.66K | $697.0K |
| 79 | Fulgent Genetics Inc. | FLGT | 0.28% | 33.44K | $665.5K |
| 80 | Contineum Therapeutics Inc. | CTNM | 0.28% | 38.53K | $662.3K |
| 81 | Zura Bio Ltd. | ZURA | 0.28% | 111.27K | $650.9K |
| 82 | Evommune Inc. | EVMN | 0.25% | 42.41K | $594.6K |
| 83 | Rezolute Inc. | RZLT | 0.24% | 113.39K | $577.2K |
| 84 | Relmada Therapeutics Inc. | RLMD | 0.24% | 123.52K | $571.9K |
| 85 | C4 Therapeutics Inc. | CCCC | 0.22% | 130.21K | $520.8K |
| 86 | Compass Therapeutics Inc. | CMPX | 0.22% | 212.08K | $509.0K |
| 87 | Enanta Pharmaceuticals Inc. | ENTA | 0.20% | 34.24K | $461.2K |
| 88 | Arcturus Therapeutics Holdings Inc. | ARCT | 0.19% | 33.46K | $450.1K |
| 89 | X4 Pharmaceuticals Inc. | XFOR | 0.19% | 111.07K | $448.7K |
| 90 | Upstream Bio Inc. | UPB | 0.19% | 64.08K | $446.7K |
| 91 | Immuneering Corp. | IMRX | 0.17% | 76.18K | $403.8K |
| 92 | Inhibikase Therapeutics Inc. | IKT | 0.16% | 155.48K | $371.6K |
| 93 | Anavex Life Sciences Corp. | AVXL | 0.15% | 109.13K | $353.6K |
| 94 | SAB Biotherapeutics Inc. | SABS | 0.14% | 90.05K | $340.4K |
| 95 | MacroGenics Inc. | MGNX | 0.13% | 74.84K | $306.9K |
| 96 | Fulcrum Therapeutics Inc. | FULC | 0.13% | 78.47K | $300.5K |
| 97 | Akebia Therapeutics Inc. | AKBA | 0.12% | 315.90K | $286.4K |
| 98 | Sionna Therapeutics Inc. | SION | 0.12% | 52.88K | $279.7K |
| 99 | NovaBridge Biosciences | NBP | 0.11% | 135.87K | $271.7K |
| 100 | Immunic Inc. | IMUX | 0.11% | 16.05K | $264.8K |
| 101 | Bicycle Therapeutics PLC | BCYC | 0.11% | 59.31K | $259.2K |
| 102 | Protara Therapeutics Inc. | TARA | 0.11% | 66.18K | $254.8K |
| 103 | Tenax Therapeutics Inc. | TENX | 0.02% | 31.24K | $54.7K |
| 104 | Novo Nordisk A/S | — | 0.00% | 1.23K | $0.12 |
| 105 | AstraZeneca PLC | — | 0.00% | 36.59K | $0.04 |
| 106 | Chinook Therapeutics Inc. | — | 0.00% | 20.70K | $0.02 |
| 107 | Cash Equivalent | USD | 0.00% | -2.87K | -$2.9K |
Klik ticker untuk melihat semua ETF yang memilikinya.
Eksposur Sektor
Eksposur Geografis
Bobot negara sebagaimana dilaporkan oleh penyedia data. Label pasar berkembang/maju/frontier mengikuti klasifikasi yang ada di halaman Metodologi. Lindung nilai mata uang: Tidak ada indikasi hedging pada nama dana.
Distribusi
| Yield (TTM) | — | Dibayarkan (12 bulan terakhir) | — |
| Frekuensi | Annual | SEC yield | Tidak disediakan oleh sumber data kami — lihat halaman penerbit |
| Tanggal ex-dividen terakhir | Dec 19, 2024 | Pembayaran terakhir | $1.1735 (Dec 26, 2024) |
| Pertumbuhan 1T | — | Pertumbuhan 3T / 5T (tahunan) | — / — |
| Tanggal ex-dividen | Tanggal Pencatatan | Tanggal pembayaran | Jumlah |
|---|---|---|---|
| Dec 19, 2024 | Dec 19, 2024 | Dec 26, 2024 | $1.1735 |
| Dec 21, 2023 | Dec 22, 2023 | Dec 27, 2023 | $0.0711 |
| Dec 19, 2019 | Dec 20, 2019 | Dec 27, 2019 | $0.0160 |
| Dec 20, 2018 | Dec 21, 2018 | Dec 27, 2018 | $0.7840 |
| Dec 21, 2017 | Dec 22, 2017 | Dec 28, 2017 | $0.5790 |
Yield distribusi trailing = total kas 12 bulan terakhir ÷ harga saat ini. Ini BUKAN yield 30 hari SEC dan distribusi tidak dijamin berlanjut. Penjelasan perbedaannya →
Statistik Risiko
| Volatilitas 1T / 3T | 30.99% / 31.04% | Sharpe 1T / 3T | 3.41 / 1.22 |
| Drawdown maks 1T / 3T | -12.66% / -42.44% | Sortino 1T | 5.70 |
| Beta vs S&P 500 (3T) | 1.02 | Korelasi vs S&P 500 (1T) | 0.383 |
| Deviasi sisi bawah 1 tahun | 18.55% | Tingkat bebas risiko yang digunakan | 3.71% (3M T-bill, FRED) |
Dihitung oleh ETF Explorer dari harga penutupan harian yang telah disesuaikan dividen; volatilitas dan drawdown merupakan angka yang disetahunkan/per periode; eksposur S&P 500 diproksikan oleh SPY. Per Aug 27, 2026. Rumus →
Likuiditas
| Volume hari ini | 22.44K | Volume rata-rata | 39.97K |
| AUM | $242.4M | Premium/Diskon | -0.78% |
| Spread bid/ask | Tidak disediakan oleh sumber data kami. Periksa layar kuotasi broker Anda; spread paling lebar pada saat pembukaan dan penutupan. | ||
Premium/discount membandingkan harga pasar tertunda dengan NAV yang terakhir dilaporkan — angka indikatif, bukan premium/discount penutupan resmi. Cara kerja likuiditas ETF →
Aliran Dana (estimasi)
| Periode | Est. arus bersih | % dari AUM awal | AUM awal → akhir |
|---|---|---|---|
| 1 Hari | $5.9M | +2.50% | $236.5M → $242.4M |
| 1 Minggu | $5.8M | +2.51% | $232.8M → $242.4M |
Estimasi ETF Explorer: perubahan AUM yang dilaporkan dikurangi dampak pergerakan pasar, dari snapshot harian kami. Bukan data kreasi/penebusan resmi penerbit.
Sumber Daya Resmi Dana
Tautan eksternal akan membuka situs penerbit atau SEC EDGAR di tab baru. Prospektus dan dokumen resmi selalu menjadi sumber yang berwenang — tinjau sebelum berinvestasi.
Berita Terkini untuk SBIO
Tidak ada artikel yang menyebut dana ini secara langsung dalam 7 hari terakhir — menampilkan liputan ETF umum.
Panduan: AUM adalah ukuran dana. Expense ratio adalah biaya tahunan yang sudah tercermin dalam imbal hasil. NAV adalah nilai aset yang dimiliki dana per unit; harga pasar bisa sedikit di atas (premium) atau di bawah (diskon) NAV. Total return mengasumsikan distribusi diinvestasikan kembali. Setiap dataset menampilkan tanggal datanya masing-masing karena kepemilikan, aset, dan harga diperbarui pada jadwal yang berbeda.